MCID: APH002
MIFTS: 60

Aphasia

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 29 55 6 43 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
MeSH 44 D001037
UMLS 73 C0003537

Summaries for Aphasia

NINDS : 54 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to epilepsy-aphasia spectrum and frontotemporal lobar degeneration with tdp43 inclusions, grn-related, and has symptoms including seizures, tremor and fever. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Memantine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 43 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 epilepsy-aphasia spectrum 34.1 CNKSR2 GRIN2A
2 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.9 GRN MAPT
3 nominal aphasia 33.9 CHMP2B GRN MAPT PSEN1
4 progressive non-fluent aphasia 33.6 C9orf72 CHMP2B GRN MAPT PSEN1
5 semantic dementia 32.7 APOE C9orf72 CHMP2B GRN MAPT PSEN1
6 agraphia 32.0 GRN MAPT PRNP PSEN1
7 pick disease of brain 31.9 APOE APP GRN MAPT PSEN1 SNCA
8 apraxia 31.7 C9orf72 FOXP2 GRN MAPT PSEN1
9 frontotemporal dementia 31.5 APOE APP C9orf72 CHMP2B GRN MAPT
10 supranuclear palsy, progressive, 1 31.3 APOE APP C9orf72 GRN MAPT PSEN1
11 alexia 30.7 APOE PSEN1
12 ideomotor apraxia 30.5 GRN MAPT
13 creutzfeldt-jakob disease 30.5 APOE MAPT PRNP
14 associative agnosia 30.3 GRN PSEN1
15 echolalia 30.1 GRN MAPT PSEN1
16 mutism 30.1 CHMP2B GRN
17 visual agnosia 29.9 GRN PSEN1
18 posterior cortical atrophy 29.9 APOE MAPT
19 akinetic mutism 29.9 MAPT PRNP
20 speech disorder 29.8 FOXP2 GRIN2A GRN
21 prion disease 29.7 APP MAPT PRNP
22 kluver-bucy syndrome 29.7 APP MAPT PSEN1
23 cerebrovascular disease 29.6 APOE APP MAPT
24 transient global amnesia 29.6 BDNF PRNP PSEN1
25 dementia 29.6 APOE APP BDNF C9orf72 CHMP2B GRN
26 alzheimer disease 29.6 APOE APP BDNF GRIN2A GRN MAPT
27 cerebral amyloid angiopathy, cst3-related 29.4 APOE APP MAPT PRNP PSEN1
28 behavioral variant of frontotemporal dementia 29.4 C9orf72 CHMP2B GRN MAPT PSEN1
29 motor neuron disease 29.3 BDNF C9orf72 GRN MAPT SNCA
30 amyotrophic lateral sclerosis 1 28.8 APP BDNF C9orf72 CHMP2B GRN MAPT
31 logopenic progressive aphasia 12.5
32 landau-kleffner syndrome 12.1
33 epilepsy, focal, with speech disorder and with or without mental retardation 12.0
34 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 12.0
35 intellectual disability-expressive aphasia-facial dysmorphism syndrome 12.0
36 masa syndrome 11.9
37 gerstmann syndrome 11.8
38 spastic paraplegia 1 11.6
39 cerebral atrophy 11.5
40 moyamoya disease 1 11.3
41 marchiafava bignami disease 11.3
42 autosomal dominant partial epilepsy with auditory features 11.1
43 sudanophilic cerebral sclerosis 10.9
44 frontotemporal dementia, chromosome 3-linked 10.9
45 progressive multifocal leukoencephalopathy 10.9
46 handl syndrome 10.9
47 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.9
48 x-linked charcot-marie-tooth disease 10.9
49 myelinoclastic diffuse sclerosis 10.9
50 frontotemporal dementia with parkinsonism-17 10.4

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


seizures, tremor, fever, dyspnea, edema, back pain, cachexia, vertigo, pain, headache, syncope, scanning speech, cyanosis, chronic pain, sciatica, sore throat, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, vertigo/dizziness, sleeplessness, other symptoms involving head and neck, swelling, mass, or lump in head and neck, aprosodia, aphasic, symptoms involving head and neck, other and unspecified speech disturbances, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.26 APOE APP BDNF C9orf72 GRIN2A GRN
2 cellular MP:0005384 10.16 APOE APP BDNF C9orf72 GRN L1CAM
3 growth/size/body region MP:0005378 10.13 APOE APP BDNF C9orf72 GRN L1CAM
4 nervous system MP:0003631 10.13 APOE APP BDNF C9orf72 CHMP2B GRIN2A
5 mortality/aging MP:0010768 10.07 APOE APP BDNF C9orf72 GRN L1CAM
6 integument MP:0010771 10.06 APOE APP BDNF GRIN2A L1CAM MAPT
7 no phenotypic analysis MP:0003012 9.91 APOE APP BDNF C9orf72 GRN L1CAM
8 reproductive system MP:0005389 9.76 APOE APP BDNF GRN L1CAM PRNP
9 taste/olfaction MP:0005394 9.26 APOE BDNF MAPT SNCA
10 vision/eye MP:0005391 9.17 APOE BDNF GRN L1CAM MAPT PRNP

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Benzocaine Approved, Investigational Phase 4,Phase 3 94-09-7, 1994-09-7 2337
5 tannic acid Approved Phase 4,Phase 3
6
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
7
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
8
Citalopram Approved Phase 4 59729-33-8 2771
9
Testosterone Approved, Investigational Phase 4 58-22-0 6013
10
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
11
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130
12 Piracetam Approved, Investigational Phase 4,Phase 1 7491-74-9
13
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
14 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
17 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
20 Cholinergic Agents Phase 4,Phase 2,Not Applicable
21 Cholinesterase Inhibitors Phase 4,Phase 2,Not Applicable
22 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Sympathomimetics Phase 4,Phase 2,Not Applicable
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Cardiotonic Agents Phase 4,Phase 2,Not Applicable
27 Analgesics Phase 4,Phase 3,Phase 2
28 Anti-Inflammatory Agents Phase 4,Phase 3
29 Fibrinolytic Agents Phase 4,Phase 3
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
31 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2
33 Antipyretics Phase 4,Phase 3
34 Cyclooxygenase Inhibitors Phase 4,Phase 3
35 Platelet Aggregation Inhibitors Phase 4,Phase 3,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable
37 Dopamine agonists Phase 4,Not Applicable
38 Psychotropic Drugs Phase 4,Phase 2,Phase 1,Not Applicable
39 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Not Applicable
40 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
41 Antidepressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
42 Serotonin Uptake Inhibitors Phase 4,Not Applicable
43 Serotonin Agents Phase 4,Not Applicable
44 Hormone Antagonists Phase 4,Phase 3
45 Hormones Phase 4,Phase 3
46 Soy Bean Phase 4
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
48 Androgens Phase 4
49 Antipsychotic Agents Phase 4
50 Serotonin Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 364)
# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
8 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
9 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
10 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
11 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
12 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
13 A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
14 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
15 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
16 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
17 Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) Unknown status NCT02817789 Phase 3 Ticagrelor alone;Combination lysine acetylsalicylate - clopidogrel
18 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
19 Action of Amantadine on Post-Stroke Aphasic Patients Completed NCT00821691 Phase 2, Phase 3 Amantadin;Placebo
20 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
21 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
22 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
23 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
24 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
25 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
26 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Recruiting NCT02618577 Phase 3 Edoxaban;ASA
27 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
28 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
29 Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. Recruiting NCT03187405 Phase 3 EVD + IVF with Alteplase
30 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
31 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
32 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
33 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
34 Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4) Terminated NCT00856661 Phase 3 Desmoteplase;Placebo
35 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
36 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Unknown status NCT02540109 Phase 2
37 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
38 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
39 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
40 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
41 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Unknown status NCT02676843 Phase 2 18F-AV-1451
42 Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury Unknown status NCT02018406 Phase 1, Phase 2 Combination injection of EPO and G-CSF;Injection of normal saline
43 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
44 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
45 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
46 Dextroamphetamine and tDCS to Improve the Fluency Completed NCT02514044 Phase 2 Dexedrine;Placebo
47 Psychosocial Wellbeing Following Stroke Completed NCT01912014 Phase 1, Phase 2
48 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed NCT00814697 Phase 2
49 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
50 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray

Search NIH Clinical Center for Aphasia

Cochrane evidence based reviews: aphasia

Genetic Tests for Aphasia

Genetic tests related to Aphasia:

# Genetic test Affiliating Genes
1 Aphasia 29

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

41
Brain, Testes, Cortex, Temporal Lobe, Eye, Prefrontal Cortex, Lung

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 1938)
# Title Authors Year
1
Exploring the efficacy of melodic intonation therapy with Broca's aphasia in Arabic. ( 29943587 )
2018
2
Sentence composition ability in two patients with non-fluent/agrammatic variant primary progressive aphasia. ( 29409157 )
2018
3
Treatment for Lexical Retrieval Impairments in Primary Progressive Aphasia: A Research Update with Implications for Clinical Practice. ( 29933491 )
2018
4
[18F]AV-1451 tau-PET and primary progressive aphasia. ( 29451323 )
2018
5
Attention control comparisons with SLT for people with aphasia following stroke: methodological concerns raised following a systematic review. ( 29911416 )
2018
6
Words fail: Lesion-symptom mapping of errors of omission in post-stroke aphasia. ( 29411521 )
2018
7
Malignant atrophic papulosis with motor aphasia and intestinal perforation: A case report and review of published works. ( 29516548 )
2018
8
Repetitive sessions of tDCS to improve naming in post-stroke aphasia: Insights from an individual patient data (IPD) meta-analysis. ( 29439369 )
2018
9
GRIN2A mutations in epilepsy-aphasia spectrum disorders. ( 29056244 )
2018
10
Pre-articulatory electrical activity associated with correct naming in individuals with aphasia. ( 29421267 )
2018
11
Tau Uptake in Agrammatic Primary Progressive Aphasia with and without Apraxia of Speech. ( 29935044 )
2018
12
Cognitive functioning in chronic post-stroke aphasia. ( 29432034 )
2018
13
Episodic and working memory function in Primary Progressive Aphasia: A meta-analysis. ( 29928907 )
2018
14
Are there prototypical associations between time frames and aspectual values? Evidence from Greek aphasia and healthy ageing. ( 29939796 )
2018
15
The Impact of Aphasia Camp Participation on Quality of Life: A Primary Progressive Aphasia Perspective. ( 29933493 )
2018
16
Proform-Antecedent Linking in Individuals with Agrammatic Aphasia: A Test of the Intervener Hypothesis. ( 29422720 )
2018
17
Long-Term maintenance of anomia treatment effects in primary progressive aphasia. ( 29380657 )
2018
18
A Life Participation Approach to Primary Progressive Aphasia Intervention. ( 29933494 )
2018
19
Rate and rhythm control strategies for apraxia of speech in nonfluent primary progressive aphasia. ( 29682238 )
2018
20
The role of language proficiency and linguistic distance in cross-linguistic treatment effects in aphasia. ( 29969313 )
2018
21
Primary progressive aphasia: a clinical approach. ( 29392464 )
2018
22
Anatomy of aphasia revisited. ( 29360947 )
2018
23
Molecular neuroimaging in primary progressive aphasia with predominant agraphia. ( 29569990 )
2018
24
Development, Cross-Cultural Adaptation, and Psychometric Characteristics of the Persian Progressive Aphasia Language Scale in Patients With Primary Progressive Aphasia: A Pilot Study. ( 29942438 )
2018
25
Barriers and facilitators to meeting aphasia guideline recommendations: what factors influence speech pathologists' practice? ( 29376450 )
2018
26
Developmental conduction aphasia after neonatal stroke. ( 29572915 )
2018
27
Atypical Kawasaki Disease Presenting with Hemiparesis and Aphasia: A Case Report. ( 29398757 )
2018
28
Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. ( 29254097 )
2018
29
Person-Centered Approaches to Communication Participation and Engagement for Individuals with Primary Progressive Aphasia and Dementia. ( 29933486 )
2018
30
Error Consistency in Acquired Apraxia of Speech With Aphasia: Effects of the Analysis Unit. ( 29392281 )
2018
31
Parkinsonism is associated with altered primary motor cortex plasticity in frontotemporal dementia-primary progressive aphasia variant. ( 29909180 )
2018
32
Transient aphasia after right-unilateral ultrabrief electroconvulsive therapy: A case report. ( 29945792 )
2018
33
A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. ( 29425241 )
2018
34
Assessment of Individuals with Primary Progressive Aphasia. ( 29933490 )
2018
35
Integration of speech and gesture in aphasia. ( 29411476 )
2018
36
Multimodal Communication in Aphasia: Perception and Production of Co-speech Gestures During Face-to-Face Conversation. ( 29962942 )
2018
37
Distinct [<sup>18</sup>F]THK5351 binding patterns in primary progressive aphasia variants. ( 29946950 )
2018
38
Further Evidence of the Positive Influence of Repetitive Transcranial Magnetic Stimulation on Speech and Language in Patients with Aphasia after Stroke: Results from a Double-Blind Intervention with Sham Condition. ( 29402816 )
2018
39
Implementing a Standardized Assessment Battery for Aphasia in Acute Care. ( 29359304 )
2018
40
The Roles of Retrieval Practice Versus Errorless Learning in Strengthening Lexical Access in Aphasia. ( 29946697 )
2018
41
Predicting Recovery in Acute Post-stroke Aphasia. ( 29451321 )
2018
42
Adult-onset epileptic aphasia. ( 29960970 )
2018
43
Maximising recovery from aphasia with central and peripheral agraphia: The benefit of sequential treatments. ( 29298550 )
2018
44
A Computational Investigation of Sources of Variability in Sentence Comprehension Difficulty in Aphasia. ( 29356427 )
2018
45
Leukoaraiosis is independently associated with naming outcome in poststroke aphasia. ( 29980639 )
2018
46
A Novel Phenotype in a Previously Described Epilepsy-Aphasia Disorder. ( 29961510 )
2018
47
Early-Onset Alzheimer Disease (EOAD) With Aphasia: A Case Report. ( 30319468 )
2018
48
Thalamic bacterial abscess presenting with hemiparesis and expressive aphasia. ( 30101064 )
2018
49
Urban-Rural Differences in Service Utilization and Costs of Care for Racial-Ethnic Groups Hospitalized With Poststroke Aphasia. ( 30102901 )
2018
50
Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. ( 30108500 )
2018

Variations for Aphasia

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.88 APP GRIN2A L1CAM PRNP PSEN1 SRPX2
2 lysosome GO:0005764 9.85 C9orf72 CHMP2B GRN SNCA
3 neuron projection GO:0043005 9.85 APP C9orf72 CNKSR2 GRIN2A MAPT PSEN1
4 glutamatergic synapse GO:0098978 9.84 APOE CHMP2B CNKSR2 GRIN2A
5 neuronal cell body GO:0043025 9.8 APOE CNKSR2 L1CAM MAPT PSEN1 SNCA
6 postsynaptic density GO:0014069 9.78 CHMP2B CNKSR2 GRIN2A PRNP
7 synaptic vesicle GO:0008021 9.73 BDNF GRIN2A SNCA
8 membrane raft GO:0045121 9.73 APP MAPT PRNP PSEN1
9 dendrite GO:0030425 9.7 APOE BDNF C9orf72 L1CAM MAPT PRNP
10 rough endoplasmic reticulum GO:0005791 9.63 APP PSEN1 SNCA
11 smooth endoplasmic reticulum GO:0005790 9.6 APP PSEN1
12 synaptic membrane GO:0097060 9.59 GRIN2A SRPX2
13 axonal growth cone GO:0044295 9.58 C9orf72 L1CAM
14 nuclear outer membrane GO:0005640 9.58 PSEN1 SNCA
15 inclusion body GO:0016234 9.57 PRNP SNCA
16 axon GO:0030424 9.5 APP BDNF C9orf72 L1CAM MAPT PSEN1
17 ciliary rootlet GO:0035253 9.49 APP PSEN1
18 main axon GO:0044304 9.43 APP C9orf72 MAPT
19 growth cone GO:0030426 9.1 APP C9orf72 L1CAM MAPT PSEN1 SNCA
20 extracellular region GO:0005576 10.11 APOE APP BDNF C9orf72 GRN MAPT
21 extracellular space GO:0005615 10.07 APOE APP BDNF C9orf72 GRN SNCA

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.89 APOE APP PSEN1 SNCA
2 autophagy GO:0006914 9.87 C9orf72 CHMP2B PSEN1
3 neuron projection development GO:0031175 9.85 APP L1CAM MAPT
4 negative regulation of neuron apoptotic process GO:0043524 9.84 APOE BDNF PSEN1 SNCA
5 response to oxidative stress GO:0006979 9.83 APOE APP PRNP PSEN1
6 memory GO:0007613 9.78 BDNF GRIN2A MAPT PSEN1
7 forebrain development GO:0030900 9.77 APP FOXP2 PSEN1
8 negative regulation of protein phosphorylation GO:0001933 9.76 C9orf72 PRNP PSEN1 SNCA
9 regulation of synaptic plasticity GO:0048167 9.75 GRIN2A MAPT PSEN1
10 learning or memory GO:0007611 9.73 APP GRIN2A PRNP PSEN1
11 positive regulation of neuron death GO:1901216 9.72 MAPT PRNP SNCA
12 positive regulation of endocytosis GO:0045807 9.69 APOE SNCA
13 ionotropic glutamate receptor signaling pathway GO:0035235 9.69 APP GRIN2A
14 positive regulation of dendritic spine development GO:0060999 9.68 APOE PSEN1
15 regulation of protein binding GO:0043393 9.68 APP PSEN1
16 regulation of long-term neuronal synaptic plasticity GO:0048169 9.68 APP SNCA
17 response to lead ion GO:0010288 9.68 APP MAPT
18 regulation of neuronal synaptic plasticity GO:0048168 9.67 APOE SNCA
19 microglial cell activation GO:0001774 9.67 MAPT SNCA
20 cellular response to copper ion GO:0071280 9.67 APP PRNP SNCA
21 positive regulation of long-term synaptic potentiation GO:1900273 9.66 APP GRIN2A
22 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.66 APP PRNP
23 regulation of phosphorylation GO:0042325 9.65 PSEN1 SRPX2
24 axon development GO:0061564 9.65 L1CAM MAPT
25 dopamine metabolic process GO:0042417 9.65 GRIN2A SNCA
26 positive regulation of receptor recycling GO:0001921 9.64 PSEN1 SNCA
27 stress granule assembly GO:0034063 9.64 C9orf72 MAPT
28 cellular copper ion homeostasis GO:0006878 9.63 APP PRNP
29 supramolecular fiber organization GO:0097435 9.63 MAPT SNCA
30 amyloid precursor protein metabolic process GO:0042982 9.62 APOE PSEN1
31 negative regulation of amyloid-beta formation GO:1902430 9.62 APOE PRNP
32 amyloid fibril formation GO:1990000 9.61 APP MAPT
33 locomotion GO:0040011 9.61 GRIN2A PSEN1
34 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.58 APP PSEN1
35 astrocyte activation GO:0048143 9.58 APP MAPT PSEN1
36 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.57 APP PSEN1
37 astrocyte activation involved in immune response GO:0002265 9.56 APP PSEN1
38 negative regulation of long-term synaptic potentiation GO:1900272 9.54 APOE APP PRNP
39 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.51 APP PSEN1
40 neuron projection maintenance GO:1990535 9.5 APP PRNP PSEN1
41 cellular response to amyloid-beta GO:1904646 9.46 APP GRIN2A PRNP PSEN1
42 modulation of age-related behavioral decline GO:0090647 9.43 APP PRNP PSEN1
43 positive regulation of amyloid fibril formation GO:1905908 9.13 APOE APP PSEN1
44 synapse organization GO:0050808 9.02 APP L1CAM MAPT PSEN1 SNCA

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tau protein binding GO:0048156 9.32 APOE SNCA
2 identical protein binding GO:0042802 9.23 APOE APP CNKSR2 FOXP2 MAPT PRNP
3 cuprous ion binding GO:1903136 9.16 PRNP SNCA
4 lipoprotein particle binding GO:0071813 8.96 APOE MAPT
5 protein binding GO:0005515 10.1 APOE APP C9orf72 CHMP2B CNKSR2 FOXP2

Sources for Aphasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....